Lijuan Zhao1, Xin Zhou2, Xia Shan3, Lian-Wen Qi4, Tongshan Wang2, Jun Zhu5, Danxia Zhu6, Zebo Huang2, Lan Zhang2, Huo Zhang2, Yin Yin7, Zhiyan Wang8, Wei Zhu9, Wenfang Cheng10, Lin Jiang11. 1. Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, PR China; Department of Endocrinology and Metabolism, Puyang Municipal Anyang Area Hospital, 260 Dengta Road, Anyang, HeNan 455000, PR China. 2. Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, PR China. 3. Department of Respiration, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210000, PR China. 4. State Key Laboratory of Natural Medicines and Department of Pharmacognosy, China Pharmaceutical University, No. 24 Tongjia Lane, Nanjing, 210009, PR China. 5. Department of Radiation Oncology, Jiangsu Cancer Hospital, No. 42 Bai Zi Ting, Nanjing 210009, PR China. 6. Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, PR China. 7. Department of Obstetrics and Gynecology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, PR China. 8. Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, PR China. 9. Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, PR China. Electronic address: zhuwei@njmu.edu.cn. 10. Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, PR China. Electronic address: chengwenfang@aliyun.com. 11. Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, PR China. Electronic address: jlinna0000@163.com.
Abstract
BACKGROUND: The altered expression of circulating miRNAs has been discovered in many autoimmune diseases (ADs). With rare existing research, it is still unclear in Hashimoto's thyroiditis (HT). We detected plasma miRNA expression of HT patients in this three-stage designed study. METHODS: Differently expressed miRNAs (4 HT pools vs. 1 normal control pool) were identified using quantitative reverse transcription polymerase chain reaction (qRT-PCR) based Exiqon panel (miRCURY-Ready-to-Use- PCR-Human- panel-I+II-V1.M) in the initial discovery stage. These miRNAs were then confirmed in the training stage and further validated in the testing stage using qRT-PCR with 64 (32 HT vs. 32 NCs) and 136 samples (68 HT vs. 68 NCs), respectively. RESULTS: A total of 10 miRNAs showed differential expression through the training stage. For further validation in the testing stage, expression of 6 miRNAs (miR-205, miR-20a-3p, miR-375, miR-296, miR-451, miR-500a) were consistent with those in the training stage. Combination results showed that these 6 miRNAs were significantly up-regulated in peripheral plasma of HT patients compared with normal controls (P<0.05). In addition, the six-miRNA signature was evaluated to be a potential diagnostic marker of HT. The areas under the receiver operating characteristic curve of the signature were 0.80, 0.75 and 0.69 for the training, testing and the combined stages, respectively. Three miRNAs were associated with TSH levels in HT patients (miR-451, P=0.043; miR-375, P=0.043; miR-500a, P=0.043). Additionally, miR-20a-3p was related with TgAb level (P=0.046). CONCLUSIONS: We identified a miRNA signature including six dysregulated plasma miRNAs which could act as a diagnostic marker in plasma of HT, providing more evidence and better understanding for the association between circulating miRNAs and autoimmune diseases.
BACKGROUND: The altered expression of circulating miRNAs has been discovered in many autoimmune diseases (ADs). With rare existing research, it is still unclear in Hashimoto's thyroiditis (HT). We detected plasma miRNA expression of HT patients in this three-stage designed study. METHODS: Differently expressed miRNAs (4 HT pools vs. 1 normal control pool) were identified using quantitative reverse transcription polymerase chain reaction (qRT-PCR) based Exiqon panel (miRCURY-Ready-to-Use- PCR-Human- panel-I+II-V1.M) in the initial discovery stage. These miRNAs were then confirmed in the training stage and further validated in the testing stage using qRT-PCR with 64 (32 HT vs. 32 NCs) and 136 samples (68 HT vs. 68 NCs), respectively. RESULTS: A total of 10 miRNAs showed differential expression through the training stage. For further validation in the testing stage, expression of 6 miRNAs (miR-205, miR-20a-3p, miR-375, miR-296, miR-451, miR-500a) were consistent with those in the training stage. Combination results showed that these 6 miRNAs were significantly up-regulated in peripheral plasma of HT patients compared with normal controls (P<0.05). In addition, the six-miRNA signature was evaluated to be a potential diagnostic marker of HT. The areas under the receiver operating characteristic curve of the signature were 0.80, 0.75 and 0.69 for the training, testing and the combined stages, respectively. Three miRNAs were associated with TSH levels in HT patients (miR-451, P=0.043; miR-375, P=0.043; miR-500a, P=0.043). Additionally, miR-20a-3p was related with TgAb level (P=0.046). CONCLUSIONS: We identified a miRNA signature including six dysregulated plasma miRNAs which could act as a diagnostic marker in plasma of HT, providing more evidence and better understanding for the association between circulating miRNAs and autoimmune diseases.
Authors: Olivia Trummer; Ines Foessl; Natascha Schweighofer; Edi Arifi; Christoph W Haudum; Sharmaine Reintar; Stefan Pilz; Verena Theiler-Schwetz; Christian Trummer; Andreas Zirlik; Albrecht Schmidt; Caterina Colantonio; Ewald Kolesnik; Nicolas Verheyen; Thomas R Pieber; Barbara Obermayer-Pietsch Journal: Genes (Basel) Date: 2022-01-19 Impact factor: 4.096